ESC: Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha

Amgen's Repatha and Sanofi and Regeneron's Praluent have been locked in a heated battle for supremacy in the pricey PCSK9 cholesterol-cutting market. Looking to angle its way to an advantage, Amgen is looking to adolescent patients with a rare disorder causing high cholesterol levels.